Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
Abstract Objective The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole. Methods The retrospective study cohort comprised 40 patients diagnosed wit...
Saved in:
Main Authors: | Yin Cao, Jun Liang, Biao Dai, Feng Shan, Qingrong Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-12-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12888-024-06437-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
by: Sanya Sharma, et al.
Published: (2023-10-01) -
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
by: Zhen Mao, et al.
Published: (2024-12-01) -
Relation of Vitamin D levels with positive and negative symptoms of schizophrenia – A hospital based cross-sectional comparative study
by: Soumitra Ghosh, et al.
Published: (2023-09-01) -
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
by: Ramandeep Kaur, et al.
Published: (2023-04-01) -
Association between treatment resistance and cognitive function in schizophrenia
by: Jiaqian Sun, et al.
Published: (2024-10-01)